Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Low Prevalence Of HPV Infection May Be Tied To Poor Prognosis For Blacks With Head And Neck Cancer
Researchers at the University of Maryland Marlene and Stewart Greenebaum Cancer have found that head and neck cancer patients who test positive for the human papillomavirus (HPV) have much better survival rates than patients who don"t have the virus, according to a new study in the journal Cancer Prevention Research. The researchers also discovered that blacks in the study had a very low rate of HPV infection, and consequently worse survival, which may explain why African-American patients traditionally have had a poor prognosis for head and neck cancer.
generic viagra online
University Of Pittsburgh Medical Center Named One Of 100 Most Wired Hospitals In The U.S. For 11th Consecutive Year
For the 11th consecutive year, the University of Pittsburgh Medical Center (UPMC) has been named one of the 100 Most Wired hospitals and health systems in the United States, according to the results of the 2009 survey by Hospitals & Health Networks magazine, the journal of the American Hospital Association. UPMC is one of only five organizations to appear on the list since its inception.
News of the day
AAMC Commends Final National Institutes of Health's Stem Cell Guidelines
AAMC (Association of American Medical Colleges) President and CEO Darrell G. Kirch, M.D., issued the following statement on the final National Institutes of Health"s (NIH) Guidelines on Human Stem Research, published today:
Sexual Health

As The Market Potential Grows, Developers Press For Keys To Delivering Systemic Drugs Via Inhalation

At a time when the drug industry is striving for patient-friendly delivery methods for new and existing drugs, the growing availability of innovative inhaler device designs is driving interest in pulmonary drug delivery technology and devices as an alternative to oral and parenteral routes of administration. While well-established for treating upper respiratory diseases such as asthma and COPD, companies competing in the inhaled drug delivery sector - major players such as GlaxoSmithKline, AstraZeneca and Boehringer Ingelheim as well as pure-play start-ups - continue to view delivery of systemic drugs via inhalation as a major opportunity. The primary reason for the attraction of systemic pulmonary drug delivery lies in converging and related trends in population demographics and disease incidence. As the median age of the global population continues to increase, conditions and diseases such as menopause, osteoporosis, diabetes, and heart disease, which require long-term therapy, are expected to become significantly more prevalent. This is driving a growing emphasis on drug self-administration for chronic conditions and greater interest in noninvasive drug delivery technology. "The historical landscape for inhaled delivery of systemic drugs is marked by disappointment," explains Paul Brooks, Greystone Associates Senior Analyst. "But advances in drug formulation and inhalation device design are moving this technology approach closer to commercialization." Several of these development-stage drug products have the potential to make a significant impact in the therapeutic markets they target, improving patient compliance and effectively changing the way important illnesses and conditions are treated. Developments in this sector are the subject of a comprehensive analysis by Greystone Associates, and are contained in a just-released report that analyzes existing and emerging systemic inhalation products, market participants, and key demand and technology factors influencing the commercial market and shaping growth in this sector. More information is available here. Greystone Associates


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009